The real-time PCR test was developed by Thermo Fisher Scientific and validated by Aeon, and detects 34 different pathogens from vaginal swabs.
The firm also announced that it plans to expand its RAS biomarker testing collaboration with Amgen in Europe.
Agilent will offer Rubicon's amplification kits alongside one of its pre-screen kits, both of which are used in reproductive health testing.
University of Cambridge researchers found that the portion of tumor DNA in patients' blood could predict treatment response and time to disease progression.
The two-hour test requires about two minutes of hands-on time to detect multiple pathogens from stool samples.
The results confirmed that circulating mutations can be reliably detected and changed during treatment, and showed that they could be a valuable prognostic biomarker.
The test is the third in the firm's line of infectious disease assays, which also includes tests for meningococcus and Group B Strep.
The firm plans to develop a line of tests on the system that could include panels for infection control, viral testing, CNS infections, and assays for immunocompromised patients.
DNANudge is developing an at-home testing kit, based on DNAe's semiconductor technology, to screen around 50 SNPs associated with nutrition and metabolism.
The deal also includes milestone payments to Carpegen and Systec totaling €2.5M and a potential for €9M in royalty-based earnings.
The firm, which makes both neurogenetic and oncology diagnostics, also provided updates on its market strategies and menu outlook.
The qPCR-based test was shown to differentiate cancerous and non-cancerous tissue and predict biochemical recurrence, and can be used on small, degraded samples.
The company plans to launch the new qNIPT test, which uses methylation-specific quantitative PCR to detect fetal epigenetic biomarkers, in the near future.
The case is being framed as either upholding a strong patent regime or dealing a blow to US-based manufacturing as part of the global supply chain.
The company's PrenaTest BioIT analysis software is now also cleared for use with a new methylation-specific qPCR assay for the detection of fetal trisomy 21.
The company has rededicated itself to a fully blood-based test pipeline, with its next assays focused on women's health, including endometriosis and ovarian, uterine, and cervical cancers.
The agreement now includes distribution of Roche's Kapa Biosystems portfolio in all geographies except the US, Brazil, and Japan.
Using enhancements to RT-PCR, the firm is able to detect all protein-coding genes in a single-tube multiplex reaction, reducing costs for large-scale projects.
The team will use the new research grant to further develop the Stockholm3 prostate cancer test and to design follow-on diagnostics to help treat patients with the disease.
The firm said the one-for-five reverse split will help address a looming delisting from the Nasdaq Capital Market by boosting the bid price per share above $1.00.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.